ASH-JSH Abstract Achievement Award
The following individuals received the ASH-JSH Abstract Achievement Award.
2023 Recipients
Kenki Saito
Nara Medical University
Persistent ADAMTS13 Inhibitor May Lead to Delayed ADAMTS13 Recovery in Japanese Patients with Caplacizumab-Treated Immune-Mediated Thrombotic Thrombocytopenic Purpura
Satoshi Kaito, MD, PhD
The University of Tokyo
Inhibition of Topors Ubiquitin Ligase Augments the Efficacy of DNA Hypomethylating Agents through DNMT1 Stabilization
Rurika Okuda, MSc, BS
Kyoto University
Clonal Evolution of Der(1;7)(q10;p10) Myeloid Neoplasms
2022 Recipients
Yuta Yamada, MD
Institute of Medical Science, The University of Tokyo
Mlkl Mediates Age-Related Attrition of Hematopoietic Stem Cells and Ineffective Hematopoiesis in Myelodysplastic Syndrome
Takao Yogo, MD
Institute of Medical Science, The University of Tokyo
Activated CMPs Act in Concert with the Spleen and Accelerate Hematopoietic Inflation after Transplantation
Shinpei Harada
Department of Hematology, Hokkaido University Faculty of Medicine
Intercellular Mitochondrial Transfer Enhances Metabolic Fitness and Anti-Tumor Effects of CAR T Cells
2021 Recipients
Yoshiaki Abe, MD
University of Tsukuba
A Single-Cell Atlas of Nonhematopoietic Cells in Human Lymph Node and Lymphoma Reveals Landscape of Stromal Remodeling
Abstract #447
June Takeda, MD
Kyoto University
EPOR/JAK/STAT Signaling Pathway As Therapeutic Target of Acute Erythroid Leukemia
Abstract #610
Koji Jimbo, MD
The University of Tokyo
Deficiency of the E3 Ligase Hoip Impairs Adult Hematopoiesis and Myeloid Leukemia
Abstract #1153
2020 Recipients
Arata Ishii, MD, PhD
Chiba University Hospital
Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell TransplantatioHTMLn: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT)
Abstract #1478
Ryunosuke Saiki, MD
Kyoto University
Combined Landscape of Gene Mutations and Copy Number Alterations in Clonal Hematopoiesis: Analysis in 10,612 Japanese Individuals
Abstract #385
Shunichiro Yasuda, MD
Tokyo Medical and Dental University
MPL Overexpression Induces a High Level of Mutant-Calr/MPL Complex: A Novel Mechanism of Ruxolitinib Resistance in Myeloproliferative Neoplasms with Calr Mutations
Abstract #1262
2019 Recipients
Haruko Shima, MD, PhD
Keio University School of Medicine
Discontinuation of Tyrosine Kinase Inhibitor in Children with Chronic Myeloid Leukemia (JPLSG STKI-14 study)
Abstract #25
Koya Ono, MD
Tohoku University Graduate School of Medicine
Molecular Characterization and Novel Therapeutic Strategy for X-Linked Sideroblastic Anemia Associated with ALAS2 Missense Variants
Abstract #3530
Takeshi Fujino, MD
The University of Tokyo
Mutant ASXL1 Promotes Expansion of the Phenotypic Hematopoietic Stem Cell Compartment
Abstract #821
2018 Recipients
Yasuyuki Arai, MD, PhD
Kyoto University
Prediction of Acute Graft-Versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation Using a Machine Learning Algorithm
Abstract #68
Tomoyasu Jo, MD
Kyoto University
Mechanisms Underlying Augmented Lymphomagenesis by LUBAC; Possible Accumulation of AID-Mediated Somatic Mutations
Abstract #775
Sousuke Nakamura, MD
University of Tokyo
Prognostic Impact of Circulating Tumor DNA Status Post-Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia and Myelodysplastic Syndrome
Abstract #247
2017 Recipients
Yasunori Kogure, MD, PhD
Graduate School of Medicine, Kyoto University
Novel Mechanism of Post-Transcriptional Regulation of PD-L1 Expression By 3’-UTR Binding Proteins
Abstract #730
Norihiro Murakami, MD
Nagoya University Graduate School of Medicine
Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia
Abstract #487
Masahiro Uni, MD, PhD
Department of Transfusion Medicine, University of Tokyo Hospital
Modeling ASXL1 Mutation Revealed Myelodysplasia Caused By Derepression of p16Ink4a Through Aberrant PRC1-Mediated Histone Modification
Abstract #118
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission